论文部分内容阅读
目的 探讨13 1Ⅰ加抗甲亢药物综合治疗Graves′病甲亢的临床可行性及价值。方法 将 2 6 5例Graves′病甲亢患者随机分为两组 :单纯13 1Ⅰ治疗组 12 3例 ,采用13 1Ⅰ一次性口服治疗 ;13 1Ⅰ加抗甲亢药物治疗组 14 2例 ,在给予13 1Ⅰ一次性口服后第 3天给予抗甲亢药物治疗 1个月 ,比较两组治疗后病情变化情况 ,观察抗甲亢药物对13 1Ⅰ治疗甲亢的疗效影响。结果 治疗 3个月时两组疗效间差别有显著性意义 (P <0 0 1) ,治疗 12个月时两组疗效间差别无显著性意义 (P >0 0 5 )。结论 甲亢患者口服13 1Ⅰ后加用抗甲亢药物治疗不会降低或增加最终疗效 ,对于大多数非重症甲亢患者 ,加用抗甲亢药物并无明显临床价值 ;但对于部分重症患者 ,在口服13 1Ⅰ 3天后加用抗甲亢药物短程治疗则有利于迅速缓解症状 ,平稳度过13 1Ⅰ充分发挥疗效之前的时期
Objective To investigate the clinical feasibility and value of 131I plus anti hyperthyroidism in the treatment of Graves’ disease and hyperthyroidism. Methods Twenty-five Graves’ disease patients with hyperthyroidism were randomly divided into two groups: 131 cases of 131 I treatment group and 131 cases of 131 cases of hyperthyroidism treatment group. After oral administration of anti-hyperthyroidism on the first 3 days after treatment for 1 month, the changes of the two groups were compared after treatment to observe the effect of anti-hyperthyroidism on the therapeutic effect of 131I treatment of hyperthyroidism. Results There was a significant difference between the two groups in efficacy at 3 months (P <0.01). There was no significant difference between the two groups at 12 months of treatment (P> 0.05). Conclusions The treatment of hyperthyroidism with 131I plus anti-hyperthyroidism does not reduce or increase the final effect. For most patients with non-severe hyperthyroidism, anti-hyperthyroidism has no obvious clinical value. However, in some severe cases, oral administration of 131I 3 days later with anti-hyperthyroidism drug short-course treatment is conducive to rapid relief of symptoms, stable over 13 1 Ⅰ give full play to the time before efficacy